One hundred and three patients with Philadelphia chromosome or BCR-ABL positive
chronic myeloid leukemia (CML) in chronic phase who were on oral imatinib were included …

Background Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine
kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a …

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75–90%
of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage …

About 75% of patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia
(CML) treated initially with imatinib achieve complete cytogenetic remission (CCyR), 1 and …

Patients not in complete cytogenetic response (CCyR) continuously face the competing
possibilities of eventually achieving a cytogenetic response versus progressing. We …

Imatinib has become the gold standard therapy for Ph+ CML, as it induces complete
cytogenetic remission (CCR) in 75–90% of patients in chronic phase (CP), and up to 40% of …

Pharmacokinetic (PK) factors have been suggested to be involved in the unfavorable clinical
responses of chronic myeloid leukemia (CML) patients treated with imatinib. The purpose of …

Imatinib mesylate (trade name Glivec® or Gleevec) is emerging as an important therapy in
the management of chronic myeloid leukaemia (CML). It is clinically useful to monitor the …

Cytogenetic and molecular responses to standard-dose imatinib (IM) were correlated with
trough IM plasma levels for 78 patients with chronic myeloid leukemia (CML) after a …

Chronic myelogenous leukemia (CML) is effectively treated with imatinib mesylate (IM), a
small molecule inhibitor of the BCR-ABL tyrosine kinase that is expressed in the entire …